Marshall Wace’s Boston Scientific BSX Stock Holding History

Marshall Wace’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.6K	Sell	200 -499,800	-100%	-$40M	﹤0.01%	3083
2025 Q4	$47.7M	Buy	+500,000	New	+$49M	0.04%	354

Other funds holding BSX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace's BSX Position: Q1 2026 in Review

Marshall Wace increased its Boston Scientific (BSX) stake by 22% in Q1 2026, buying an estimated $52.3M and bringing the position to 3,611,020 shares worth $227M. The position accounts for 0.23% of the portfolio, ranked #64.

Marshall Wace first reported a position in BSX in Q3 2014 and has held it in 46 quarters since. The position peaked at $957M in Q3 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

Marshall Wace held 3,611,020 shares of Boston Scientific worth $227M as of Q1 2026.
Marshall Wace bought 653,783 Boston Scientific shares in Q1 2026, an estimated $52.3M.
Boston Scientific made up 0.23% of Marshall Wace's portfolio in Q1 2026, its #64 holding.
Marshall Wace first reported a position in Boston Scientific in Q3 2014 and has held it in 46 quarters since.
Marshall Wace's Boston Scientific position peaked at $957M in Q3 2025.
1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.